ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR)

Historical Holders from Q3 2014 to Q3 2025

Type / Class
Equity / Ordinary Shares, nominal value Euro 0.04 per share
Symbol
PRQR on Nasdaq
Shares outstanding
105,365,368
Price per share
$2.13
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
37,542,716
Total reported value
$79,967,112
% of total 13F portfolios
0%
Share change
-2,931,586
Value change
-$6,233,029
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
63
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VAN HERK INVESTMENTS B.V. 14% +7.7% $31,668,615 +$2,331,550 14,329,690 +7.9% Van Herk Investments B.V. 29 Sep 2025
Adage Capital Management, L.P. 6.3% -18% $13,467,954 -$3,060,326 6,601,938 -19% Adage Capital Management, L.P. 30 Jun 2025
As of 30 Sep 2025, ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) has 63 institutional shareholders filing 13F forms. They hold 37,542,716 shares. of 105,365,368 outstanding shares (36%) .

Top 25 institutional shareholders own 34% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
ADAGE CAPITAL PARTNERS GP, L.L.C. 5.9% 6,253,467 -5.3% 0.02% $13,319,885
Privium Fund Management B.V. 4.7% 4,998,287 +0.01% 1.9% $10,646,351
Affinity Asset Advisors, LLC 3.4% 3,600,000 +2.9% 0.71% $7,668,000
MORGAN STANLEY 2.8% 2,901,202 -5.9% 0% $6,179,561
Aberdeen Group plc 2.2% 2,298,823 +24% 0.01% $4,896,493
Sio Capital Management, LLC 2% 2,075,139 0% 1.1% $4,420,046
Kynam Capital Management, LP 1.6% 1,649,462 0% 0.26% $3,513,354
DAFNA Capital Management LLC 1.5% 1,567,561 0% 0.82% $3,338,905
Siren, L.L.C. 1.5% 1,552,183 0% 0.13% $3,306,150
ArrowMark Colorado Holdings LLC 1.2% 1,246,234 +3.9% 0.05% $2,654,478
PLATINUM INVESTMENT MANAGEMENT LTD 1.2% 1,235,514 -15% 0.17% $2,631,645
M28 Capital Management LP 0.97% 1,019,498 0% 3.2% $2,171,531
Ikarian Capital, LLC 0.85% 892,229 +2.8% 0.43% $1,900,447
Point72 Asset Management, L.P. 0.71% 750,000 0% 0% $1,597,500
CITADEL ADVISORS LLC 0.62% 657,012 +73% 0% $1,399,436
MACQUARIE GROUP LTD 0.59% 620,000 0% 0% $1,321,000
Walleye Capital LLC 0.5% 531,977 0% 0.01% $1,133,111
Monaco Asset Management SAM 0.44% 460,000 0% 0.36% $979,800
TWO SIGMA INVESTMENTS, LP 0.4% 417,300 +86% 0% $888,849
NORTHERN TRUST CORP 0.28% 294,742 -25% 0% $627,801
BOOTHBAY FUND MANAGEMENT, LLC 0.24% 248,290 +11% 0.01% $528,858
MILLENNIUM MANAGEMENT LLC 0.23% 240,622 -82% 0% $512,525
TWO SIGMA ADVISERS, LP 0.22% 228,600 +63% 0% $486,918
Palo Alto Investors LP 0.18% 188,807 0.07% $402,159
DIADEMA PARTNERS LP 0.15% 157,694 0% 0.23% $335,888

Institutional Holders of ProQR Therapeutics N.V. - Ordinary Shares, nominal value Euro 0.04 per share (PRQR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q3 37,542,716 $79,967,112 -$6,233,029 213% 63
2025 Q2 40,456,202 $82,379,793 -$1,567,787 204% 61
2025 Q1 41,291,570 $54,918,956 -$5,787,634 133% 63
2024 Q4 44,400,171 $117,660,809 +$75,460,214 265% 73
2024 Q3 17,443,866 $31,743,198 +$264,551 182% 45
2024 Q2 17,290,486 $28,649,850 -$212,173 166% 47
2024 Q1 17,387,392 $39,773,390 -$2,232,071 228.99% 48
2023 Q4 18,391,369 $36,955,484 -$1,048 198% 46
2023 Q3 18,716,181 $24,328,704 -$3,600,707 130% 45
2023 Q2 21,135,686 $34,237,327 -$2,165,096 162% 50
2023 Q1 22,307,671 $47,513,184 +$11,076,011 213% 53
2022 Q4 16,678,999 $59,949,585 -$4,783,345 370% 44
2022 Q3 20,737,577 $15,488,034 -$756,614 74.39% 40
2022 Q2 21,732,005 $16,900,344 -$8,618,537 77.78% 46
2022 Q1 31,584,585 $28,589,297 -$92,011,334 90.52% 55
2021 Q4 45,389,080 $364,328,631 +$6,653,069 800.98% 70
2021 Q3 39,831,678 $333,392,000 +$12,185,511 837% 65
2021 Q2 38,480,836 $259,363,000 -$31,751,363 674.01% 62
2021 Q1 43,322,291 $286,359,000 +$120,606,551 661% 63
2020 Q4 25,217,186 $105,911,100 -$8,198,557 419.99% 44
2020 Q3 28,012,135 $134,190,000 -$5,871,461 479.01% 39
2020 Q2 29,097,654 $176,912,000 -$841,663 607.99% 42
2020 Q1 29,331,943 $161,028,000 -$7,201,007 548.98% 41
2019 Q4 30,150,188 $298,791,000 +$87,230,706 991.02% 51
2019 Q3 21,657,785 $124,747,000 -$19,152,638 575.97% 46
2019 Q2 23,591,614 $214,685,000 -$8,496,818 910% 51
2019 Q1 23,900,548 $331,501,291 +$9,453,144 1,387% 52
2018 Q4 23,051,868 $363,615,000 +$53,059,884 1,578% 56
2018 Q3 19,515,607 $375,509,129 +$166,447,646 1,935.01% 35
2018 Q2 11,069,586 $80,808,000 +$5,443,360 730% 24
2018 Q1 10,687,432 $32,865,000 -$2,756,889 307.53% 23
2017 Q4 11,507,590 $37,110,000 +$4,386,222 322.45% 25
2017 Q3 10,077,120 $48,873,000 +$5,208,606 484.99% 22
2017 Q2 9,002,972 $46,815,000 +$1,972,554 520% 17
2017 Q1 9,009,830 $45,049,000 +$634,077 500% 19
2016 Q4 8,888,833 $43,556,000 +$398,181 490% 21
2016 Q3 8,692,509 $57,980,000 -$2,944,713 666.99% 25
2016 Q2 9,151,395 $44,281,000 -$2,331,033 483.99% 26
2016 Q1 9,587,274 $46,786,000 -$10,738,149 487.99% 28
2015 Q4 11,189,723 $97,062,000 -$3,472,541 867.93% 32
2015 Q3 11,137,806 $162,244,000 +$4,007,870 1,457% 35
2015 Q2 10,833,771 $180,564,000 -$5,703,246 1,667.04% 35
2015 Q1 11,013,724 $241,352,000 +$65,736,744 2,188.04% 37
2014 Q4 8,018,201 $172,936,000 +$8,842,880 2,166.97% 35
2014 Q3 7,627,734 $129,886,000 +$129,886,015 1,719% 30